Repaglinide--a new compound for the treatment of patients with type 2 diabetes.

@article{Wolffenbuttel1999RepaglinideaNC,
  title={Repaglinide--a new compound for the treatment of patients with type 2 diabetes.},
  author={Bruce H. R. Wolffenbuttel},
  journal={The Netherlands journal of medicine},
  year={1999},
  volume={55 5},
  pages={
          229-34
        }
}
Repaglinide is a new oral blood glucose lowering agent, a member of the carbamoylmethyl benzoic acid (CMBA) family. Its mechanism of action is partly similar to that of the sulphonylurea: the release of insulin from the pancreatic beta cells is stimulated by closure of ATP-dependent potassium channels. However, repaglinide regulates these channels via a different binding site on the beta cell than glibenclamide, and the drug does not cause insulin release in the absence of glucose, or during… CONTINUE READING